The MF treatment landscape is evolving with new JAK inhibitors and combination therapies improving patient outcomes. Leading companies including Incyte, Sierra Oncology, and CTI BioPharma are driving innovation in targeted treatments that address anemia, splenomegaly, and constitutional symptoms. Diagnostic advancements and personalized treatment approaches are enhancing clinical management strategies.
Access Full Report: https://shorturl.at/GFWha
Mi piace
Commento
Condividi
